Respiratory Syncytial Virus InfectionsPhase 2NCT04681833
Safety and Efficacy of BARS13 in the Elderly
A Phase 2 study testing Recombinant Respiratory Syncytial Virus Vaccine (BARS13) in people with Respiratory Syncytial Virus Infections, run by Advaccine (Suzhou) Biopharmaceuticals Co., Ltd. at 2 sites in Australia.
Trial summary
Advaccine Clinical Research are developing a vaccine called BARS13 for the active immunisation of infants (aged 6 months to 5 years old) and the elderly (aged 60-80 years old) for the seasonal prevention of Respiratory Syncytial Virus (RSV) infection. Read more about this study
- Who is it for?
- Ages 60 to 80 yearsHealthy volunteers can take part
- Conditions the study is for
- Respiratory Syncytial Virus Infections
- What is being tested?
- Recombinant Respiratory Syncytial Virus Vaccine (BARS13)
- Type of treatment
- Vaccines, Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 125 participants
- Where
- 2 sitesAustralia
- Study dates
- 24 May 2021to 2 Apr 2024
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 60 to 80 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Participants who meet all of the following criteria at screening are eligible to participate in the study:
- Healthy male or female adults, or adults with stable chronic disease aged 60 to 80 years old, inclusive. Stable disease includes adults with no new diagnosis, hospitalization or changes in medication in the preceding 3 months. Adults with stable, Stage 1 chronic obstructive pulmonary disease (COPD) are eligible for this study provided they are not using inhaled or systemic corticosteroids.
- Body mass index (BMI) ≤40 kg/m2.
- Screening 12-lead electrocardiogram (ECG) must be within normal range (QT interval corrected using Fridericia's formula [QTcF] males ≤ 450 msec; females ≤ 470 msec) or with abnormalities, which are not hazardous to the patient according to the opinion of the Investigator at the screening visit.
- Hematology, serum chemistry, coagulation and urinalysis test results not deviating from the normal reference range by age and gender to a clinically relevant extent at screening.
- Systolic blood pressure in the range of 90 to 160 mmHg (inclusive) and diastolic blood pressure in the range of 50 to 95 mmHg (inclusive) after 5 minutes in supine position at the screening visit. (May be repeated twice, if abnormal values were recorded in the first instance, at the discretion of the PI).
Show all 11Show fewer
- Willing and able (on both a physical and cognitive basis) to give informed consent prior to study enrolment.
- Able to comply with study requirements, including access to transportation for study visits.
- Access to inbound and outbound telephone communication with caregivers and study staff.
- Males must be surgically sterile (>30 days since vasectomy with no viable sperm), abstinent or, if engaged in sexual relations with a person of child-bearing potential, the participant and his partner must use an acceptable, highly effective, contraceptive method from screening and for a period of at least 3 months after the last dose of study drug. Acceptable methods of contraception are the use of condoms and an effective contraceptive for the female partner that could include surgical sterilization (e.g., bilateral tubal ligation), hormonal contraception, or intrauterine contraception/device. The PI or appropriate designee is to assess the adequacy of methods of contraception on a case-by-case basis.
- Females must be of nonchildbearing potential i.e., surgically sterilized (hysterectomy, bilateral salpingectomy, bilateral oophorectomy at least 6 weeks before screening) or postmenopausal (where postmenopausal is defined as no menses for 12 months without an alternative medical cause and a follicle-stimulating hormone level ≥40 IU/L at the screening visit).
Who cannot join
- Participants who meet any of the following criteria are not eligible to participate in the study:
- Participation in research involving investigational product (IP) (drug / biologic / device) within 45 days before the planned date of the Day 1 vaccination.
- History of a serious reaction to any prior vaccination.
- Received any vaccine other than an inactivated or live attenuated influenza vaccine or coronavirus SARS-COV-2 (COVID-19) vaccine (not in a clinical trial setting) in the 4 weeks preceding the first study vaccination; or any RSV vaccine at any time or who plan to receive any non-study vaccines within 28 days of the last dose of study vaccine. Influenza vaccine and coronavirus SARS-COV-2 (COVID-19) vaccine should not be given within 14 days of each dose of study vaccine.
- Any known or suspected immunosuppressive condition, acquired or congenital, as determined by history and/or physical examination.
- Chronic administration (defined as more than 14 continuous days) of immunosuppressants or other immune-modifying drugs within 6 months prior to the administration of the study vaccine. An immunosuppressant dose of glucocorticoid will be defined as a systemic dose ≥10 mg of prednisone per day or equivalent. The use of topical and nasal glucocorticoids will be permitted.
Show all 19Show fewer
- Positive testing for active HIV, HBsAg, HCV, Quantiferon (TB infection).
- Positive urine drug screen at screening, or pre-vaccination for any drug of abuse unless there is an explanation acceptable to the PI (e.g., the participant stated in advance that they consumed a prescription or over the counter product which contained the detected drug) and/or the participant had a negative urine drug screen on retest by the pathology laboratory.
- A positive alcohol breathalyzer test at screening or pre-vaccination.
- Administration of immunoglobulins and/or any blood products within the 3 months preceding the administration of the study vaccine or during the study.
- Acute disease at the time of enrolment (defined as the presence of a moderate or severe illness with or without fever, or an oral temperature ≥38.0°C on the planned day of vaccine administration).
- Suspicion or recent history (within one year of planned vaccination) of alcohol or other substance abuse (regular consumption of > 10 units of alcohol/week [men and women]; 1 unit = 237 mL of beer, 25 mL shot of 40% spirit or a 125 mL glass of wine. A standard drink contains 10 g of alcohol).
- Birthmarks, tattoos, wound or other skin conditions over the deltoid region of either arm that, in the PI's opinion, could reasonably obscure and interfere with evaluation of local injection site reactions.
- Subject with a history of autoimmune disease or an active autoimmune disease requiring therapeutic intervention including but not limited to: systemic or cutaneous lupus erythematosus, autoimmune arthritis/rheumatoid arthritis, Guillain-Barré syndrome, multiple sclerosis, Sjögren syndrome, idiopathic thrombocytopenic purpura, autoimmune glomerulonephritis, autoimmune thyroiditis, giant cell arteritis (temporal arteritis), psoriasis, and insulin-dependent diabetes mellitus (Type 1), Crohn's disease or ulcerative colitis.
- Any condition that in the opinion of the investigator would pose a health risk to the subject if enrolled or could interfere with evaluation of the vaccine or interpretation of study results (including neurologic, cognitive, or psychiatric conditions deemed likely to impair the quality of study compliance or safety reporting).
- History of any chronic respiratory illness, including current diagnosis of asthma within 2 years, COPD ≥ Stage 2, exercise induced wheezing, reactive airway disease, emphysema, chronic bronchitis or cystic fibrosis. Asthma diagnosed > 2 years ago is allowed at PI discretion if the asthma is considered well controlled as per the Asthma Australia Control Tool (score of ≥20 out of 25). Inhaled corticosteroids are allowed provided dose is considered <10 mg prednisolone equivalent.
- Any respiratory illness (e.g., cough, sore throat, dyspnea, wheezing or nocturnal awakenings to respiratory symptoms) within 14 days prior to receiving the first dose of study vaccination.
- Any active pulmonary infection or other inflammatory conditions, even in the absence of febrile episodes, within 14 days prior to the first study vaccination.
- Any other condition or prior therapy that in the opinion of the PI would make the volunteer unsuitable for this study, including inability to cooperate fully with the requirements of the study protocol or likelihood of noncompliance with any study requirements.
Trial locations and contacts
2 sites in 1 country.
Australia2 sites
CMAX Clinical Research
Adelaide, South Australia
Q-Pharm Pty Ltd
Herston, Queensland, 4006
About this study
Official title: A Randomised, Double-blind, Placebo-controlled, Dose-ranging Phase II Study in 60 to 80-Year-Old Adults to Assess the Safety and Immunogenicity of BARS13
Advaccine Clinical Research are developing a vaccine called BARS13 for the active immunisation of infants (aged 6 months to 5 years old) and the elderly (aged 60-80 years old) for the seasonal prevention of Respiratory Syncytial Virus (RSV) infection. A total of 125 volunteers aged 60 - 80 years (inclusive) will be enrolled in this study, and will be divided into 3 groups (or 'cohorts') of 40 people (cohort 1 and 2) and 45 people (cohort 3). The aim of the study is to evaluate the safety and tolerability of BARS13 in this age group.
Read the detailed description
Advaccine Clinical Research is developing a recombinant Respiratory Syncytial Virus (rRSV) vaccine - BARS13 for the protection of the elderly from RSV infection.
This is a two centre, randomised, double-blind, placebo-controlled study in healthy adults aged 60-80 years old to evaluate the safety and immunogenicity of the rRSV investigational vaccine, BARS13.
This study will be conducted in two centres in Australia with CMAX as the coordinating site.
A total of up to 125 eligible participants will be enrolled administered by IM injection to the deltoid region of the arm. Cohort 1 (low repeat dose) includes one dose of 10micrograms of the vaccine on one arm and one dose of placebo on the other arm given sequentially on Day 1 and 29. Cohort 2 (high repeat dose) includes one dose of 10micrograms of the vaccine on each arm given sequentially on Day 1 and 29. Cohort 3 (high repeat multiple dose) includes one dose of 10microgarms of vaccine to each arm sequentially on Day 1, 29 and 57.
- Conditions
- Respiratory Syncytial Virus Infections
- Being tested
- Recombinant Respiratory Syncytial Virus Vaccine (BARS13) /placebo, Recombinant Respiratory Syncytial Virus Vaccine (BARS13), Placebo
- Keywords
- Respiratory Syncytial Virus (RSV), BARS13, Vaccines, Virus Diseases
- Medical subject headings
- Respiratory Syncytial Virus Infections, Virus Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Recombinant Respiratory Syncytial Virus Vaccine (BARS13) /placeboDrug
Low Repeat Dose
Recombinant Respiratory Syncytial Virus Vaccine (BARS13)Drug
High Repeat Dose/High Repeat Multiple Dose
PlaceboDrug
Liquid diluent/Lyophilised Powder
| Study group | Role | What they receive |
|---|---|---|
| Cohort 1: BARS13 low repeat dose | Experimental | Active: One dose of 10 μg rRSV G protein/10 μg CsA administered by IM injection to the deltoid region of one arm, and one dose of placebo by IM injection to the deltoid region of the other arm, given sequentially (10 μg rRSV G protein/10 μg CsA in total for each vaccination) on Day 1 and 29. Receives: Drug: Recombinant Respiratory Syncytial Virus Vaccine (BARS13) /placebo |
| Cohort 1: BARS13 placebo low repeat dose | Placebo comparator | Placebo: One dose administered by IM injection to both arms, on Day 1 and 29. Receives: Drug: Placebo |
| Cohort 2: BARS13 high repeat dose | Experimental | Active: One dose of 10 μg rRSV G protein/10 μg CsA administered by IM injection to the deltoid region of each arm, given sequentially (20 μg rRSV G protein/20 μg CsA in total for each vaccination) on Day 1 and 29. Receives: Drug: Recombinant Respiratory Syncytial Virus Vaccine (BARS13) |
| Cohort 2: BARS13 placebo high repeat dose | Placebo comparator | Placebo: One dose administered by IM injection to both arms, on Day 1 and 29. Receives: Drug: Placebo |
| Cohort 3: BARS13 high repeat multiple dose | Experimental | Active: One dose of 10 μg rRSV G protein/10 μg CsA administered by IM injection to the deltoid region of each arm, given sequentially (20 μg rRSV G protein/20 μg CsA in total for each vaccination) on Day 1, Day 29 and Day 57. Receives: Drug: Recombinant Respiratory Syncytial Virus Vaccine (BARS13) |
| Cohort 3: BARS13 placebo high repeat multiple dose | Placebo comparator | Placebo: One dose administered by IM injection to both arms, on Day 1, Day 29 and Day 57. Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence and severity of vaccine-related AEs, including the following solicited AEs
Incidence and severity of local reactions (pain, tenderness, erythema, swelling, other e.g., ulceration, scabs, bruising, itching and paraesthesia) at the site of vaccination; Incidence and severity of systemic reactions (fatigue, myalgia, malaise, fever, rigors, arthralgia, nausea, diarrhea, light-headedness, dizziness, hypersensitivity and headache). Any 'solicited' AE with onset outside the specified 7-day period of follow-up will be reported as an unsolicited AE.
Measured: From baseline (Day 1) to the end of Day 7.
Incidence and severity of vaccine-related AEs, including the following solicited AEs
Incidence and severity of local reactions (pain, tenderness, erythema, swelling, other e.g., ulceration, scabs, bruising, itching and paraesthesia) at the site of vaccination; Incidence and severity of systemic reactions (fatigue, myalgia, malaise, fever, rigors, arthralgia, nausea, diarrhea, light-headedness, dizziness, hypersensitivity and headache). Any 'solicited' AE with onset outside the specified 7-day period of follow-up will be reported as an unsolicited AE.
Measured: From Day 28 to the end of Day 35.
Incidence and severity of vaccine-related AEs, including the following solicited AEs
Incidence and severity of local reactions (pain, tenderness, erythema, swelling, other e.g., ulceration, scabs, bruising, itching and paraesthesia) at the site of vaccination; Incidence and severity of systemic reactions (fatigue, myalgia, malaise, fever, rigors, arthralgia, nausea, diarrhea, light-headedness, dizziness, hypersensitivity and headache). Any 'solicited' AE with onset outside the specified 7-day period of follow-up will be reported as an unsolicited AE.
Measured: From Day 57 to the end of Day 64 (only for multiple high repeat dose group).
Occurrence of AEs
An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment.
Measured: From baseline (Day 1) to the end of the 7-day, 28-day follow up period after each vaccination
Occurrence of any AE during a 60-minute post-vaccination safety observation period
An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment.
Measured: On Day 1 (all cohorts), Day 29 (all cohorts) and Day 57 (Cohort 3 only)
Occurrence of any AE leading to withdrawal
An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment.
Measured: During the 28-day follow up period after each vaccination
Occurrence of any serious adverse event (SAE)
A SAE is any untoward medical occurrence that, at any dose: • Results in death; • Is life-threatening, (NOTE: The term 'life-threatening' in the definition of 'serious' refers to an event/reaction in which the participant was at risk of death at the time of the event/reaction; it does not refer to an event/reaction which hypothetically might have caused death, if it were more severe); • Requires inpatient hospitalization or prolongation of an existing hospitalization; • Results in persistent or significant disability/incapacity; • Is a congenital anomaly/birth defect; • Is a medically important event or reaction.
Measured: From baseline (Day 1) to the last visit, assessed up to 14 months
Occurrence of any clinically significant clinical laboratory abnormalities
Measured as Toxicity Grade ≥1.
Measured: From baseline (Day 1) to the last visit, assessed up to 14 months
Treatment-emergent, clinically significant changes in vital signs and physical examinations.
Vital signs include systolic and diastolic blood pressures, respiratory rate, pulse rate and oral temperature.
Measured: At specified intervals after each vaccination on Day 1 (all cohorts), Day 29 (all cohorts) and Day 57 (Cohort 3 only)
Secondary outcomes (4)
Humoral response to BARS13
IgG antibody titres measured by enzyme-linked immunosorbent assay (ELISA) prior to each vaccination (Day 1 and Day 29 for all cohorts, and Day 57 for Cohort 3 only), as well as at follow-up visits at 4, 8, 16, 24, 32, 40 and 52 weeks post last dose, expressed as follows: Corrected post-dose GMTs of IgG (GP)
Measured: Prior to each vaccination (Day 1 and Day 29 for all cohorts, and Day 57 for Cohort 3 only)
Humoral response to BARS13
IgG antibody titres measured by enzyme-linked immunosorbent assay (ELISA) prior to each vaccination (Day 1 and Day 29 for all cohorts, and Day 57 for Cohort 3 only), as well as at follow-up visits at 4, 8, 16, 24, 32, 40 and 52 weeks post last dose, expressed as follows: Corrected post-dose GMTs of IgG (GP)
Measured: At follow-up visits at 4, 8, 16, 24, 32, 40 and 52 weeks post last dose
Humoral response to BARS13
IgG antibody titres measured by enzyme-linked immunosorbent assay (ELISA) prior to each vaccination (Day 1 and Day 29 for all cohorts, and Day 57 for Cohort 3 only), as well as at follow-up visits at 4, 8, 16, 24, 32, 40 and 52 weeks post last dose, expressed as follows: Post-dose geometric mean fold rises (GMFRs) from baseline of IgG (GP)
Measured: Prior to each vaccination (Day 1 and Day 29 for all cohorts, and Day 57 for Cohort 3 only)
Humoral response to BARS13
IgG antibody titres measured by enzyme-linked immunosorbent assay (ELISA) prior to each vaccination (Day 1 and Day 29 for all cohorts, and Day 57 for Cohort 3 only), as well as at follow-up visits at 4, 8, 16, 24, 32, 40 and 52 weeks post last dose, expressed as follows: Post-dose geometric mean fold rises (GMFRs) from baseline of IgG (GP)
Measured: At follow-up visits at 4, 8, 16, 24, 32, 40 and 52 weeks post last dose
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Dec 2020
- Study start24 May 2021
- Primary completion26 Jan 2024
- Study completion2 Apr 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Respiratory Syncytial Virus InfectionsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Active: One dose of 10 μg rRSV G protein/10 μg CsA administered by IM injection to the deltoid region of one arm, and one dose of placebo by IM injection to the deltoid region of the other arm, given sequentially (10 μg rRSV G protein/10 μg CsA in total for each vaccination) on Day 1 and 29. Placebo: One dose administered by IM injection to both arms, on Day 1 and 29. Active: One dose of 10 μg rRSV G protein/10 μg CsA administered by IM injection to the deltoid region of each arm, given sequentially (20 μg rRSV G protein/20 μg CsA in total for each vaccination) on Day 1 and 29. Placebo: One dose administered by IM injection to both arms, on Day 1 and 29. Active: One dose of 10 μg rRSV G protein/10 μg CsA administered by IM injection to the deltoid region of each arm, given sequentially (20 μg rRSV G protein/20 μg CsA in total for each vaccination) on Day 1, Day 29 and Day 57. Placebo: One dose administered by IM injection to both arms, on Day 1, Day 29 and Day 57.
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 125 participants (actual)
Sponsor and investigators
- Lead sponsor
- Advaccine (Suzhou) Biopharmaceuticals Co., Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Natasha Martin, MBBS, Principal investigator, CMAX Clinical Research Pty Ltd
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04681833
- Sponsor's protocol ID
- ADVA-BARS13-002
- Status last verified
- Sep 2024
- First submitted
- 14 Dec 2020
- Last updated
- 20 Sep 2024
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: The results of this clinical trial may be published or presented at scientific meetings. If this is foreseen, the Investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments. The Sponsor will comply with the requirements for publication of clinical trial results. In accordance with standard editorial and ethical practice, the Sponsor will generally support publication of multicentre studies only in their entirety and not as individual site data. In this case, a coordinating Investigator will be designated by mutual agreement. Authorship will be determined by mutual agreement and in line with International Committee of Medical Journal Editors authorship requirements.
Study at a glance
From the registry record, last updated by the sponsor on 20 Sep 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomised, Double-blind, Placebo-controlled, Dose-ranging Phase II Study in 60 to 80-Year-Old Adults to Assess the Safety and Immunogenicity of BARS13
- ClinicalTrials.gov ID
- NCT04681833
- Acronym / sponsor ID
- ADVA-BARS13-002
- Conditions
- Respiratory Syncytial Virus Infections
- Keywords
- Respiratory Syncytial Virus (RSV), BARS13, Vaccines, Virus Diseases
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 125 participants (actual)
- Lead sponsor
- Advaccine (Suzhou) Biopharmaceuticals Co., Ltd.Industry (pharma, biotech, devices)
- Study start
- 24 May 2021 (actual)
- Primary completion
- 26 Jan 2024 (actual)
- Study completion
- 2 Apr 2024 (actual)
- First posted
- 23 Dec 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Advaccine Clinical Research are developing a vaccine called BARS13 for the active immunisation of infants (aged 6 months to 5 years old) and the elderly (aged 60-80 years old) for the seasonal prevention of Respiratory Syncytial Virus (RSV) infection. A total of 125 volunteers aged 60 - 80 years (inclusive) will be enrolled in this study, and will be divided into 3 groups (or 'cohorts') of 40 people (cohort 1 and 2) and 45 people (cohort 3). The aim of the study is to evaluate the safety and tolerability of BARS13 in this age group.
Detailed description
Advaccine Clinical Research is developing a recombinant Respiratory Syncytial Virus (rRSV) vaccine - BARS13 for the protection of the elderly from RSV infection.
This is a two centre, randomised, double-blind, placebo-controlled study in healthy adults aged 60-80 years old to evaluate the safety and immunogenicity of the rRSV investigational vaccine, BARS13.
This study will be conducted in two centres in Australia with CMAX as the coordinating site.
A total of up to 125 eligible participants will be enrolled administered by IM injection to the deltoid region of the arm. Cohort 1 (low repeat dose) includes one dose of 10micrograms of the vaccine on one arm and one dose of placebo on the other arm given sequentially on Day 1 and 29. Cohort 2 (high repeat dose) includes one dose of 10micrograms of the vaccine on each arm given sequentially on Day 1 and 29. Cohort 3 (high repeat multiple dose) includes one dose of 10microgarms of vaccine to each arm sequentially on Day 1, 29 and 57.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 6
- Model description
- Active: One dose of 10 μg rRSV G protein/10 μg CsA administered by IM injection to the deltoid region of one arm, and one dose of placebo by IM injection to the deltoid region of the other arm, given sequentially (10 μg rRSV G protein/10 μg CsA in total for each vaccination) on Day 1 and 29. Placebo: One dose administered by IM injection to both arms, on Day 1 and 29. Active: One dose of 10 μg rRSV G protein/10 μg CsA administered by IM injection to the deltoid region of each arm, given sequentially (20 μg rRSV G protein/20 μg CsA in total for each vaccination) on Day 1 and 29. Placebo: One dose administered by IM injection to both arms, on Day 1 and 29. Active: One dose of 10 μg rRSV G protein/10 μg CsA administered by IM injection to the deltoid region of each arm, given sequentially (20 μg rRSV G protein/20 μg CsA in total for each vaccination) on Day 1, Day 29 and Day 57. Placebo: One dose administered by IM injection to both arms, on Day 1, Day 29 and Day 57.
| Arm | Type | Receives |
|---|---|---|
| Cohort 1: BARS13 low repeat dose | Experimental | Drug: Recombinant Respiratory Syncytial Virus Vaccine (BARS13) /placeboActive: One dose of 10 μg rRSV G protein/10 μg CsA administered by IM injection to the deltoid region of one arm, and one dose of placebo by IM injection to the deltoid region of the other arm, given sequentially (10 μg rRSV G protein/10 μg CsA in total for each vaccination) on Day 1 and 29. |
| Cohort 1: BARS13 placebo low repeat dose | Placebo comparator | Drug: PlaceboPlacebo: One dose administered by IM injection to both arms, on Day 1 and 29. |
| Cohort 2: BARS13 high repeat dose | Experimental | Drug: Recombinant Respiratory Syncytial Virus Vaccine (BARS13)Active: One dose of 10 μg rRSV G protein/10 μg CsA administered by IM injection to the deltoid region of each arm, given sequentially (20 μg rRSV G protein/20 μg CsA in total for each vaccination) on Day 1 and 29. |
| Cohort 2: BARS13 placebo high repeat dose | Placebo comparator | Drug: PlaceboPlacebo: One dose administered by IM injection to both arms, on Day 1 and 29. |
| Cohort 3: BARS13 high repeat multiple dose | Experimental | Drug: Recombinant Respiratory Syncytial Virus Vaccine (BARS13)Active: One dose of 10 μg rRSV G protein/10 μg CsA administered by IM injection to the deltoid region of each arm, given sequentially (20 μg rRSV G protein/20 μg CsA in total for each vaccination) on Day 1, Day 29 and Day 57. |
| Cohort 3: BARS13 placebo high repeat multiple dose | Placebo comparator | Drug: PlaceboPlacebo: One dose administered by IM injection to both arms, on Day 1, Day 29 and Day 57. |
Who may qualify
- Ages
- 60 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (11 listed)
- Participants who meet all of the following criteria at screening are eligible to participate in the study:
- Healthy male or female adults, or adults with stable chronic disease aged 60 to 80 years old, inclusive. Stable disease includes adults with no new diagnosis, hospitalization or changes in medication in the preceding 3 months. Adults with stable, Stage 1 chronic obstructive pulmonary disease (COPD) are eligible for this study provided they are not using inhaled or systemic corticosteroids.
- Body mass index (BMI) ≤40 kg/m2.
- Screening 12-lead electrocardiogram (ECG) must be within normal range (QT interval corrected using Fridericia's formula [QTcF] males ≤ 450 msec; females ≤ 470 msec) or with abnormalities, which are not hazardous to the patient according to the opinion of the Investigator at the screening visit.
- Hematology, serum chemistry, coagulation and urinalysis test results not deviating from the normal reference range by age and gender to a clinically relevant extent at screening.
Key exclusion criteria (19 listed)
- Participants who meet any of the following criteria are not eligible to participate in the study:
- Participation in research involving investigational product (IP) (drug / biologic / device) within 45 days before the planned date of the Day 1 vaccination.
- History of a serious reaction to any prior vaccination.
- Received any vaccine other than an inactivated or live attenuated influenza vaccine or coronavirus SARS-COV-2 (COVID-19) vaccine (not in a clinical trial setting) in the 4 weeks preceding the first study vaccination; or any RSV vaccine at any time or who plan to receive any non-study vaccines within 28 days of the last dose of study vaccine. Influenza vaccine and coronavirus SARS-COV-2 (COVID-19) vaccine should not be given within 14 days of each dose of study vaccine.
- Any known or suspected immunosuppressive condition, acquired or congenital, as determined by history and/or physical examination.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Recombinant Respiratory Syncytial Virus Vaccine (BARS13) /placeboLow Repeat Dose | Drug | Cohort 1: BARS13 low repeat dose |
| Recombinant Respiratory Syncytial Virus Vaccine (BARS13)High Repeat Dose/High Repeat Multiple Dose | Drug | Cohort 2: BARS13 high repeat dose, Cohort 3: BARS13 high repeat multiple dose |
| PlaceboLiquid diluent/Lyophilised Powder | Drug | Cohort 1: BARS13 placebo low repeat dose, Cohort 2: BARS13 placebo high repeat dose, Cohort 3: BARS13 placebo high repeat multiple dose |
Primary outcome
Incidence and severity of vaccine-related AEs, including the following solicited AEs
Time frame: From baseline (Day 1) to the end of Day 7.
Incidence and severity of local reactions (pain, tenderness, erythema, swelling, other e.g., ulceration, scabs, bruising, itching and paraesthesia) at the site of vaccination; Incidence and severity of systemic reactions (fatigue, myalgia, malaise, fever, rigors, arthralgia, nausea, diarrhea, light-headedness, dizziness, hypersensitivity and headache). Any 'solicited' AE with onset outside the specified 7-day period of follow-up will be reported as an unsolicited AE.
Incidence and severity of vaccine-related AEs, including the following solicited AEs
Time frame: From Day 28 to the end of Day 35.
Incidence and severity of local reactions (pain, tenderness, erythema, swelling, other e.g., ulceration, scabs, bruising, itching and paraesthesia) at the site of vaccination; Incidence and severity of systemic reactions (fatigue, myalgia, malaise, fever, rigors, arthralgia, nausea, diarrhea, light-headedness, dizziness, hypersensitivity and headache). Any 'solicited' AE with onset outside the specified 7-day period of follow-up will be reported as an unsolicited AE.
Incidence and severity of vaccine-related AEs, including the following solicited AEs
Time frame: From Day 57 to the end of Day 64 (only for multiple high repeat dose group).
Incidence and severity of local reactions (pain, tenderness, erythema, swelling, other e.g., ulceration, scabs, bruising, itching and paraesthesia) at the site of vaccination; Incidence and severity of systemic reactions (fatigue, myalgia, malaise, fever, rigors, arthralgia, nausea, diarrhea, light-headedness, dizziness, hypersensitivity and headache). Any 'solicited' AE with onset outside the specified 7-day period of follow-up will be reported as an unsolicited AE.
Occurrence of AEs
Time frame: From baseline (Day 1) to the end of the 7-day, 28-day follow up period after each vaccination
An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment.
Occurrence of any AE during a 60-minute post-vaccination safety observation period
Time frame: On Day 1 (all cohorts), Day 29 (all cohorts) and Day 57 (Cohort 3 only)
An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment.
Occurrence of any AE leading to withdrawal
Time frame: During the 28-day follow up period after each vaccination
An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment.
Occurrence of any serious adverse event (SAE)
Time frame: From baseline (Day 1) to the last visit, assessed up to 14 months
A SAE is any untoward medical occurrence that, at any dose: • Results in death; • Is life-threatening, (NOTE: The term 'life-threatening' in the definition of 'serious' refers to an event/reaction in which the participant was at risk of death at the time of the event/reaction; it does not refer to an event/reaction which hypothetically might have caused death, if it were more severe); • Requires inpatient hospitalization or prolongation of an existing hospitalization; • Results in persistent or significant disability/incapacity; • Is a congenital anomaly/birth defect; • Is a medically important event or reaction.
Occurrence of any clinically significant clinical laboratory abnormalities
Time frame: From baseline (Day 1) to the last visit, assessed up to 14 months
Measured as Toxicity Grade ≥1.
Treatment-emergent, clinically significant changes in vital signs and physical examinations.
Time frame: At specified intervals after each vaccination on Day 1 (all cohorts), Day 29 (all cohorts) and Day 57 (Cohort 3 only)
Vital signs include systolic and diastolic blood pressures, respiratory rate, pulse rate and oral temperature.
4 secondary outcomes
Humoral response to BARS13
Time frame: Prior to each vaccination (Day 1 and Day 29 for all cohorts, and Day 57 for Cohort 3 only)
Humoral response to BARS13
Time frame: At follow-up visits at 4, 8, 16, 24, 32, 40 and 52 weeks post last dose
Humoral response to BARS13
Time frame: Prior to each vaccination (Day 1 and Day 29 for all cohorts, and Day 57 for Cohort 3 only)
Humoral response to BARS13
Time frame: At follow-up visits at 4, 8, 16, 24, 32, 40 and 52 weeks post last dose
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Sep 2024.
- Individual participant dataSharing planned: No. The results of this clinical trial may be published or presented at scientific meetings. If this is foreseen, the Investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments. The Sponsor will comply with the requirements for publication of clinical trial results. In accordance with standard editorial and ethical practice, the Sponsor will generally support publication of multicentre studies only in their entirety and not as individual site data. In this case, a coordinating Investigator will be designated by mutual agreement. Authorship will be determined by mutual agreement and in line with International Committee of Medical Journal Editors authorship requirements.
Related trials for Respiratory Syncytial Virus Infections
RecruitingPhase 3
Study to Learn About a Respiratory Syncytial Virus Vaccine in Children at High Risk of RSV Disease
Respiratory Syncytial Virus (RSV)
Active, not recruitingPhase 3
A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of Respiratory Syncytial Virus Disease
Respiratory Syncytial Virus Infections
Active, not recruitingPhase 1
A Phase 1 Study to Evaluate JCXH-108, an mRNA-based Vaccine Against RSV
Respiratory Syncytial Virus (RSV), Infectious Disease
RecruitingPhase 2
Immunogenicity of RSVPreF3 Vaccine in Immunocompromised Persons
Respiratory Syncytial Virus (RSV)
RecruitingObservational study
TARSILA Real-World Evidence Study
Respiratory Syncytial Virus (RSV), Maternal Immunization
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Natasha Martin, MBBS principal investigator
CMAX Clinical Research Pty Ltd
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Recombinant Respiratory Syncytial Virus Vaccine (BARS13) in people with Respiratory Syncytial Virus Infections, run by Advaccine (Suzhou) Biopharmaceuticals Co., Ltd. at 2 sites in Australia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 11 inclusion and 19 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 20 Sep 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Australia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence and severity of vaccine-related AEs, including the following solicited AEs (time frame: From baseline (Day 1) to the end of Day 7.). The study lists 9 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Sep 2024.